This is the authors' abstract. We don't add key points for this paper.
These results indicate that BX795 treatment is effective, and might be a safe approach to promote RB-340-1F lentiviral transduction of human primary T cells. This approach might also be helpful for other T cell therapy products that need delivery of complicated platform via large payload lentiviral vectors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: